The latest announcement is out from 23andMe Holding (ME).
23andMe Holding Co. announced promising preliminary safety and efficacy data for their innovative anti-CD200R1 antibody, 23ME-00610, at the prestigious 2024 ASCO Annual Meeting. This exciting development has not been officially filed for regulatory purposes but offers potential future implications for the company’s stakeholders and the medical community keen on advancements in clinical treatments.
For detailed information about ME stock, go to TipRanks’ Stock Analysis page.
